Clinical Trial Update: LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring a lower maintenance dose of ticagrelor in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Beijing Anzhen Hospital | Conditions: Antiplatelet Therapy, Coronary Artery Disease | Phase 4 | Status: UNKNOWN